Cargando…
Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents
Many investigational drugs with antidepressant activity are currently explored in different phases of clinical research, with indications such as major depressive disorder, treatment-resistant major depression, bipolar depression, post-partum depression, and late-life depression. Although the vast m...
Autor principal: | Vasiliu, Octavian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284317/ https://www.ncbi.nlm.nih.gov/pubmed/35847011 http://dx.doi.org/10.3389/fphar.2022.884155 |
Ejemplares similares
-
Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents
por: Vasiliu, Octavian
Publicado: (2022) -
Glutamatergic transmission in drug reward: implications for drug addiction
por: D'Souza, Manoranjan S.
Publicado: (2015) -
Synergy of Glutamatergic and Cholinergic Modulation Induces Plateau Potentials in Hippocampal OLM Interneurons
por: Hagger-Vaughan, Nicholas, et al.
Publicado: (2019) -
Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer’s Disease
por: Cheng, Yu-Jung, et al.
Publicado: (2021) -
Inflammation in stroke: the role of cholinergic, purinergic and glutamatergic signaling
por: Martín, Abraham, et al.
Publicado: (2018)